MCM
LUCD icon

Masters Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Masters Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.6M Hold
4,000,000
– – 0.15% 78
2025
Q4 		$4.36M Buy
4,000,000
+727
+0% +$813 0.18% 70
2025
Q3 		$4.04M Buy
3,999,273
+1,272,000
+47% +$1.39M 0.15% 72
2025
Q2 		$3.14M Hold
2,727,273
– – 0.12% 65
2025
Q1 		$4.06M Buy
+2,727,273
New +$3.27M 0.2% 63

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return

Masters Capital Management's LUCD Position: Q1 2026 in Review

Masters Capital Management held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 4,000,000 shares worth $4.6M. The position accounts for 0.15% of the portfolio, ranked #78.

Masters Capital Management first reported a position in LUCD in Q1 2025 and has held it in 5 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Masters Capital Management held 4,000,000 shares of Lucid Diagnostics worth $4.6M as of Q1 2026.
  • Masters Capital Management left its Lucid Diagnostics share count unchanged in Q1 2026.
  • Lucid Diagnostics made up 0.15% of Masters Capital Management's portfolio in Q1 2026, its #78 holding.
  • Masters Capital Management first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 5 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Masters Capital Management's 13F filing for Q1 2026, filed 15 May 2026.